Brief: Destiny Pharma To Finalise Phase 3 Plans For Xf-73 Nasal
22/12/2022 07:26
Dec 22 (Reuters) - Destiny Pharma PLC DEST.L :
* DESTINY PHARMA PLC - YEAR END TRADING UPDATE
* DESTINY PHARMA PLC - TO FINALISE OUR PHASE 3 PLANS FOR
XF-73
NASAL AND INTENSIFY PARTNERING DISCUSSIONS
* DESTINY PHARMA - HEADLINE TERMS AGREED STATE THAT ALL
FUTURE
CLINICAL DEVELOPMENT AND COMMERCIALISATION OF NTCD-M3 IN US WILL
BE FUNDED BY PARTNER
Source text for Eikon: ID:nRSV5306Ka
Further company coverage: DEST.L
((Reuters.Briefs@thomsonreuters.com;))